4279. Package #151 (Cervical screening with p16 and Ki-67: PAP test using liquid cytology (BD SurePath technology, FDA approved). CYTOLOGICAL PASSPORT (BD FocalPoint technology, FDA approved), PCR. HPV HCR 14 genotypes, quantitative determination, p16, Ki-67
Turnaround time (days): 3
3210 ₴
Important information
*FOR WOMEN ONLY
*An operator specifies the day of the menstrual cycle or the gestational age
*For the test ordering a special doctor's referral is required
Description
Package No. 151 – is the most comprehensive cervical screening option, designed to ensure maximum accuracy and reliability of results. It not only helps detect precancerous cervical changes but also assesses their potential risk, helping to avoid unnecessary invasive procedures.
The package includes: Pap test using BD SurePath™ liquid-based cytology with automated BD FocalPoint™ analysis (Cytology Passport) – a modern technology for early detection of precancerous and malignant changes.
At Synevo, this test is performed using a dual-review approach:
- by experienced cytologists;
- using the BD FocalPoint™ GS Imaging System (Becton Dickinson, USA) with the ZEISS Axioscope 5 microscope (Carl Zeiss, Germany).
This combination significantly improves the sensitivity and reliability of detecting abnormal cells at the earliest stages when treatment is most effective. PCR test for high-risk HPV (14 genotypes, quantitative analysis) – a method that detects HPV infection, identifies specific genotypes, and determines viral load. This is especially important since types 16 and 18 account for over 70% of cervical cancer cases. p16 and Ki-67 markers – specific biomarkers that help distinguish transient (temporary) changes from clinically significant precancerous lesions (CIN2+). Using these markers reduces the number of unnecessary biopsies and allows physicians to more accurately assess the risk of disease progression.
When and who needs the test?
- Screening and diagnosis of precancerous cervical diseases;
- screening and diagnosis of cervical cancer;
- detection of cervical pathology and monitoring of treatment effectiveness;
- exclusion of malignant epithelial transformation of the cervix in cases of high-risk HPV infection using proliferation markers.
Biological material
- Site-specific scrapings collected depending on the test
- Scrapes from various sites depending on the test
Preparing for urogenital sampling
- Collect the material before starting treatment with antibacterial/antifungal drugs (general and local action).
- In case of treatment monitoring – 14 days after the end of the course of treatment with antibacterial/antifungal drugs.
- Avoid sexual intercourse for 3 days.
- Exclude douching and the use of vaginal...